BAYER AG
๐ฉ๐ชGermany
- Country
- ๐ฉ๐ชGermany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Inhibition of Ovulation and Pharmacokinetics of Transdermal Ethinylestradiol (EE) and Gestodene (GSD)
Phase 2
Completed
- Conditions
- ContraceptionOvulation Inhibition
- Interventions
- Drug: Ethinylestradiol/Gestodene (BAY86-5016)
- First Posted Date
- 2009-06-08
- Last Posted Date
- 2014-10-28
- Lead Sponsor
- Bayer
- Target Recruit Count
- 108
- Registration Number
- NCT00915915
EU/LA Pearl Index Study - Transdermal Contraceptive Patch
Phase 3
Completed
- Conditions
- Contraception
- Interventions
- Drug: Ethinylestradiol/Gestodene (BAY86-5016)
- First Posted Date
- 2009-06-05
- Last Posted Date
- 2014-12-05
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1694
- Registration Number
- NCT00914693
Effects of Wellnara on Climacteric Symptoms
Completed
- Conditions
- Postmenopause
- Interventions
- Drug: E2/LNG oral (Wellnara, BAY86-5029)
- First Posted Date
- 2009-06-04
- Last Posted Date
- 2015-04-22
- Lead Sponsor
- Bayer
- Target Recruit Count
- 749
- Registration Number
- NCT00913926
SALTO - Epidemiological Study on Compliance and Treatment Satisfaction
Completed
- Conditions
- Thromboembolism
- Interventions
- Behavioral: No Drug
- First Posted Date
- 2009-06-01
- Last Posted Date
- 2013-09-19
- Lead Sponsor
- Bayer
- Target Recruit Count
- 480
- Registration Number
- NCT00911001
Study Investigating the Efficacy and Safety of a Contraceptive Patch for 13 Cycles
Phase 3
Completed
- Conditions
- Contraception
- Interventions
- Drug: Gestodene/EE Patch (BAY86-5016)
- First Posted Date
- 2009-06-01
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1502
- Registration Number
- NCT00910637
- Locations
- ๐บ๐ธ
Rosemark Women Care Specialist, Idaho Falls, Idaho, United States
๐บ๐ธAdvances in Health, inc., Houston, Texas, United States
๐บ๐ธThe Woman's Hospital of Texas, Houston, Texas, United States
BAY63-2521 - Long-term Extension Study in Patients With Chronic Thromboembolic Pulmonary Hypertension
- First Posted Date
- 2009-05-29
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Bayer
- Target Recruit Count
- 237
- Registration Number
- NCT00910429
- Locations
- ๐ฎ๐ฑ
Rabin Medical Center - Beilinson Campus, Petach Tikva, Israel
๐ต๐นCentro Hospitalar de Lisboa Norte - Hospital Santa Maria, Lisboa, Portugal
BAY81-8781, I.V. Aspirin in the Indication of Acute Coronary Syndrome (ACS)
Phase 3
Completed
- Conditions
- Acute Coronary Syndrome
- Interventions
- Drug: Acetylsalicylic acid (Aspirin, BAYe4465) 300 mg TabletDrug: D,L-lysine acetylsalicylate (Aspirin, BAY81-8781) 500 mg IVDrug: D,L-lysine acetylsalicylate (Aspirin, BAY81-8781) 250 mg IV
- First Posted Date
- 2009-05-29
- Last Posted Date
- 2015-06-25
- Lead Sponsor
- Bayer
- Target Recruit Count
- 270
- Registration Number
- NCT00910065
Effect on Primary Dysmenorrhea
Phase 3
Completed
- Conditions
- Primary Dysmenorrhea
- Interventions
- Drug: Ethinyl estradiol, Levonorgestrel (Miranova)Drug: Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Drug: Placebo Match to SH T00658IDDrug: Placebo Match to SH D593B
- First Posted Date
- 2009-05-29
- Last Posted Date
- 2015-08-24
- Lead Sponsor
- Bayer
- Target Recruit Count
- 507
- Registration Number
- NCT00909857
Cipro Inhaler for Cystic Fibrosis Children Ages 6-12
- First Posted Date
- 2009-05-29
- Last Posted Date
- 2013-11-21
- Lead Sponsor
- Bayer
- Target Recruit Count
- 19
- Registration Number
- NCT00910351
Bonefos and the Consumption of Analgesics
Completed
- Conditions
- Bone Neoplasms
- Interventions
- Drug: Bonefos (Clodronate, BAY94-8393)
- First Posted Date
- 2009-05-27
- Last Posted Date
- 2012-04-06
- Lead Sponsor
- Bayer
- Target Recruit Count
- 149
- Registration Number
- NCT00909142
ยฉ Copyright 2025. All Rights Reserved by MedPath